David Amsellem

Jason Butler

Kristen Kluska

Raghuram Selvaraju

Thomas Flaten

Denis Reznik

François Brisebois

Gary Nachman

James Molloy

Roanna Clarissa Ruiz

Andreas Argyrides

Daniel Smith

Mazahir Alimohamed

Nelson Cox

- Aquestive Therapeutics, Inc. filed a Current Report on Form 8-K on **October 1, 2025**, to furnish an investor presentation.  **[1398733_0001398733-25-000020_aqst-20251001.htm:0]** **[1398733_0001398733-25-000020_aqst-20251001.htm:1]** 
- The company's lead asset, Anaphylm (dibutepinephrine) Sublingual Film, has a PDUFA action date scheduled for **January 31, 2026**, following its NDA submission in Q2 2025 and acceptance in Q3 2025.  **[1398733_0001398733-25-000020_corporatepresentationoct.htm:4]**  
- Aquestive completed an equity raise of **$85 million** on **August 14, 2025**, and secured strategic funding with RTW Investments, LP, providing a cash runway into **2027**.  **[1398733_0001398733-25-000020_corporatepresentationoct.htm:6]** 
- The U.S. epinephrine market is projected to grow to **~$2 billion** in value by **2031**, representing a significant opportunity for Anaphylm if approved.   
- The company is also advancing AQST-108 (epinephrine) Topical Gel, with an Investigational New Drug (IND) application expected to be opened in **Q4 2025** for a Phase 2a clinical study in alopecia areata.  **[1398733_0001398733-25-000020_corporatepresentationoct.htm:4]**

Aquestive Therapeutics Files Investor Presentation 8-K with Anaphylm Update and Capital Raise

Aquestive Therapeutics (AQST)